HC Wainwright Issues Optimistic Forecast for MSLE Earnings

Satellos Bioscience Inc. (NASDAQ:MSLE) – Analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of Satellos Bioscience in a research report issued on Monday, March 30th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.48). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. HC Wainwright also issued estimates for Satellos Bioscience’s Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.45) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.50) EPS, FY2027 earnings at ($1.78) EPS, FY2028 earnings at ($1.89) EPS and FY2029 earnings at ($1.21) EPS.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11).

MSLE has been the subject of several other research reports. Wall Street Zen downgraded shares of Satellos Bioscience to a “strong sell” rating in a report on Saturday, March 14th. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a research report on Wednesday, March 11th. They set an “overweight” rating on the stock. Finally, Weiss Ratings assumed coverage on shares of Satellos Bioscience in a report on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Satellos Bioscience has a consensus rating of “Hold” and an average target price of $11.00.

Satellos Bioscience Stock Up 7.3%

NASDAQ:MSLE opened at $6.04 on Wednesday. The firm has a market capitalization of $93.38 million, a PE ratio of -3.90 and a beta of 1.37. Satellos Bioscience has a 1 year low of $4.53 and a 1 year high of $13.39.

Key Stories Impacting Satellos Bioscience

Here are the key news stories impacting Satellos Bioscience this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS estimates (Q2 & Q3 2026, Q4 2026, Q2 & Q3 2027) and boosted FY2026/FY2027 outlooks, reflecting smaller expected losses in the nearer quarters — a potential positive catalyst for sentiment and valuation.
• Positive Sentiment: The analyst maintained a “Buy” rating and an $11.00 price target, signaling continued analyst conviction in upside from current levels and supporting investor interest.
• Neutral Sentiment: HC Wainwright published a long‑range FY2030 estimate (EPS $0.34) that implies a substantial turnaround, but this is distant and speculative; treat as a long‑term scenario rather than near‑term proof. Article Title
• Negative Sentiment: There are also downward revisions: Q1 2027 was cut (to a larger expected loss) and HC Wainwright trimmed FY2028 and FY2029 EPS (wider losses than previously modeled). These longer‑dated negative revisions increase uncertainty around the sustainability of the recovery.
• Negative Sentiment: Satellos reported an EPS miss in its most recent quarter (reported loss larger than consensus), a likely driver of some of the model adjustments and a reminder of execution risk going forward.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.